Thalidomide-NH-CH2-COOH is utilized in the development of targeted cancer therapies due to its ability to bind to specific proteins involved in tumor growth. It is often incorporated into proteolysis-targeting chimeras (PROTACs) to degrade disease-causing proteins selectively. This compound is also explored in immunomodulatory treatments, particularly for conditions like multiple myeloma, where it helps regulate immune responses. Additionally, its modified structure enhances its stability and efficacy in drug delivery systems, making it a valuable component in pharmaceutical research and development.